Jin Bo, Dong Yu, Wang Hui-min, Huang Jin-su, Han Bao-hui
Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China.
Acta Pharmacol Sin. 2014 Mar;35(3):373-80. doi: 10.1038/aps.2013.164. Epub 2014 Feb 3.
To evaluate the relationship between epidermal growth factor receptor (EGFR) mutations and serum carcinoembryonic antigen (CEA) levels in Chinese nonsmokers with pulmonary adenocarcinoma.
We sequenced exons 18-21 of the EGFR gene in 98 cases. The patients were divided into two groups based on their pre-treatment serum CEA levels (below or above 5 ng/mL) for analyzing the correlations with EGFR mutations.
Sixty-seven cases harbored EGFR mutations. The rates of EGFR mutations and exon 19 mutations in the high-CEA group (78.2% and 49.1%, respectively) were significantly higher those in the low-CEA group (55.8% and 20.9%, respectively). Serum CEA levels were found to be the only independent predictor of EGFR mutation (OR 2.837; 95% CI: 1.178-6.829) and exon 19 mutation (OR 3.618; 95% CI: 1.319-9.918). Furthermore, a higher serum CEA level was associated with a higher EGFR mutation rate and a higher exon 19 mutation rate: patients with serum CEA levels <5 ng/mL, ≥5 and <20 ng/mL, ≥20 ng/mL showed the EGFR mutation rate of 55.8%, 74.1%, 82.1%, respectively, and the exon 19 mutation rate of 20.9%, 40.7%, 57.1%, respectively. Patients with EGFR mutations displayed a significantly higher incidence of abnormal serum CEA levels (>5 ng/mL) than patients without EGFR mutations (64.2% vs 38.7%).
Elevated serum CEA levels predict the presence of EGFR gene mutations in Chinese nonsmokers with pulmonary adenocarcinoma.
评估中国非吸烟肺腺癌患者表皮生长因子受体(EGFR)突变与血清癌胚抗原(CEA)水平之间的关系。
我们对98例患者的EGFR基因第18 - 21外显子进行了测序。根据治疗前血清CEA水平(低于或高于5 ng/mL)将患者分为两组,以分析其与EGFR突变的相关性。
67例患者存在EGFR突变。高CEA组的EGFR突变率和第19外显子突变率(分别为78.2%和49.1%)显著高于低CEA组(分别为55.8%和20.9%)。血清CEA水平是EGFR突变(比值比2.837;95%置信区间:1.178 - 6.829)和第19外显子突变(比值比3.618;95%置信区间:1.319 - 9.918)的唯一独立预测因素。此外,血清CEA水平越高,EGFR突变率和第19外显子突变率越高:血清CEA水平<5 ng/mL、≥5且<20 ng/mL、≥20 ng/mL的患者,其EGFR突变率分别为55.8%、74.1%、82.1%,第19外显子突变率分别为20.9%、40.7%、57.1%。与无EGFR突变的患者相比,有EGFR突变的患者血清CEA水平异常(>5 ng/mL)的发生率显著更高(64.